Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228.
Where this comes from
- Record sourced from PubMed, PMID 34011888.
- Also identified by DOI 10.1097/AOG.0000000000004401.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Uterine leiomyomas (fibroids) are the most common solid and symptomatic neoplasm in women. They are the leading indication for hysterectomy (1, 2), which is a definitive and effective surgical treatment for leiomyoma. However, many patients benefit from and seek out management options other than hysterectomy because they desire future childbearing or wish to retain their uterus. The purpose of this Practice Bulletin is to provide updated evidence-based recommendations for the medical, procedural, and surgical management of symptomatic leiomyomas. Discussion of the use of morcellation in the surgical management of leiomyomas is beyond the scope of this document and is addressed in a separate American College of Obstetricians and Gynecologists (ACOG) publication (3).
Medical subject headings
- Contraceptive Agents, Hormonal
- Gonadotropin-Releasing Hormone
- Intrauterine Devices, Medicated
- Leiomyoma
- Levonorgestrel
- Uterine Neoplasms